Spruce Biosciences
(NASDAQ:SPRB)
$0.64
-0.0321[-4.78%]
At close: Jun 14
$0.64
0[0.00%]
After Hours: 7:25PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$3.00
Lowest Price Target1
$3.00
Consensus Price Target1
$2.73

Spruce Biosciences (NASDAQ:SPRB) Stock, Analyst Ratings, Price Targets, Predictions

Spruce Biosciences Inc has a consensus price target of $2.73, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, RBC Capital, and JMP Securities on June 13, 2024, March 14, 2024, and March 14, 2024. With an average price target of $2.67 between Oppenheimer, RBC Capital, and JMP Securities, there's an implied 316.67% upside for Spruce Biosciences Inc from these 3 analyst ratings.

Analyst Trends and Forecast
1
Feb
1
4
Mar
1
May
1
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.5
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Oppenheimer
HC Wainwright & Co.
RBC Capital
JMP Securities
Leerink Partners

1calculated from analyst ratings

Analyst Ratings for Spruce Biosciences

Buy NowGet Alert
06/13/2024Buy Now368.75%Oppenheimer
Hartaj Singh
$4 → $3MaintainsOutperformGet Alert
06/05/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju
Reiterates → NeutralGet Alert
05/14/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju
Reiterates → NeutralGet Alert
03/14/2024Buy Now212.5%RBC Capital
Gregory Renza
$9 → $2DowngradeOutperform → Sector PerformGet Alert
03/14/2024Buy Now368.75%JMP Securities
Jonathan Wolleben
$8 → $3MaintainsMarket OutperformGet Alert
03/14/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju
DowngradeBuy → NeutralGet Alert
03/14/2024Buy Now212.5%Leerink Partners
Joseph Schwartz
$9 → $2DowngradeOutperform → Market PerformGet Alert
03/14/2024Buy NowLadenburg Thalmann
Aydin Huseynov
DowngradeBuy → NeutralGet Alert
03/14/2024Buy NowGuggenheim
Evan Wang
DowngradeBuy → NeutralGet Alert
03/05/2024Buy Now1306.25%RBC Capital
Gregory Renza
→ $9ReiteratesOutperform → OutperformGet Alert
02/26/2024Buy Now1306.25%RBC Capital
Gregory Renza
$8 → $9MaintainsOutperformGet Alert
02/21/2024Buy Now1462.5%Guggenheim
Evan Wang
→ $10Initiates → BuyGet Alert
11/20/2023Buy Now1462.5%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
09/13/2023Buy Now1150%RBC Capital
Gregory Renza
→ $8ReiteratesOutperform → OutperformGet Alert
09/13/2023Buy Now1462.5%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now1306.25%SVB Leerink
Joseph Schwartz
$3 → $9UpgradeMarket Perform → OutperformGet Alert
08/18/2023Buy Now993.75%Oppenheimer
Hartaj Singh
$8 → $7MaintainsOutperformGet Alert
08/18/2023Buy Now1462.5%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
08/16/2023Buy Now1150%JMP Securities
Jonathan Wolleben
$7 → $8MaintainsOutperformGet Alert
08/15/2023Buy Now1150%RBC Capital
Gregory Renza
→ $8ReiteratesOutperform → OutperformGet Alert
06/13/2023Buy Now1462.5%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
05/23/2023Buy Now1150%Oppenheimer
Hartaj Singh
→ $8ReiteratesOutperform → OutperformGet Alert
05/16/2023Buy Now1150%RBC Capital
Gregory Renza
→ $8ReiteratesOutperform → OutperformGet Alert
05/16/2023Buy Now993.75%JMP Securities
Jonathan Wolleben
→ $7ReiteratesMarket Outperform → Market OutperformGet Alert
05/16/2023Buy Now525%Credit Suisse
Tiago Fauth
→ $4ReiteratesOutperform → OutperformGet Alert
03/23/2023Buy Now1462.5%HC Wainwright & Co.
Raghuram Selvaraju
$20 → $10MaintainsBuyGet Alert
03/20/2023Buy Now1150%RBC Capital
Gregory Renza
→ $8Reiterates → OutperformGet Alert
03/17/2023Buy Now993.75%JMP Securities
Jonathan Wolleben
→ $7MaintainsMarket OutperformGet Alert
03/17/2023Buy Now525%Credit Suisse
Tiago Fauth
→ $4Reiterates → OutperformGet Alert
02/13/2023Buy Now1150%RBC Capital
Gregory Renza
$9 → $8MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Spruce Biosciences (SPRB) stock?

A

The latest price target for Spruce Biosciences (NASDAQ:SPRB) was reported by Oppenheimer on June 13, 2024. The analyst firm set a price target for $3.00 expecting SPRB to rise to within 12 months (a possible 368.75% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Spruce Biosciences (SPRB)?

A

The latest analyst rating for Spruce Biosciences (NASDAQ:SPRB) was provided by Oppenheimer, and Spruce Biosciences maintained their outperform rating.

Q

When was the last upgrade for Spruce Biosciences (SPRB)?

A

The last upgrade for Spruce Biosciences Inc happened on September 8, 2023 when SVB Leerink raised their price target to $9. SVB Leerink previously had a market perform for Spruce Biosciences Inc.

Q

When was the last downgrade for Spruce Biosciences (SPRB)?

A

The last downgrade for Spruce Biosciences Inc happened on March 14, 2024 when RBC Capital changed their price target from $9 to $2 for Spruce Biosciences Inc.

Q

When is the next analyst rating going to be posted or updated for Spruce Biosciences (SPRB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.

Q

Is the Analyst Rating Spruce Biosciences (SPRB) correct?

A

While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a maintained with a price target of $4.00 to $3.00. The current price Spruce Biosciences (SPRB) is trading at is $0.64, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch